Effective targeted therapy strategies are still lacking for the 15-20% of melanoma patients whose melanomas are driven by oncogenic NRAS. Here, we report on the NRAS-specific behavior of amuvatinib, a kinase inhibitor with activity against c-KIT, Axl, PDGFRα, and Rad51. An analysis of BRAF-mutant and NRAS-mutant melanoma cell lines showed the NRAS-mutant cohort to be enriched for targets of amuvatinib, including Axl, c-KIT, and the Axl ligand Gas6. Increasing concentrations of amuvatinib selectively inhibited the growth of NRAS-mutant, but not BRAF-mutant melanoma cell lines, an effect associated with induction of S-phase and G2/M-phase cell cycle arrest and induction of apoptosis. Mechanistically, amuvatinib was noted to either inhibit Axl, AKT, and MAPK signaling or Axl and AKT signaling and to induce a DNA damage response. In threedimensional cell culture experiments, amuvatinib was cytotoxic against NRAS-mutant melanoma cell lines. Thus, we show for the first time that amuvatinib has proapoptotic activity against melanoma cell lines, with selectivity observed for those harboring oncogenic NRAS. Melanoma Res 24:448-453
Introduction
Genetic profiling has provided new avenues for targeted therapy, offering a paradigm whereby kinase inhibitors with defined activity profiles can be matched to tumors with specific driver mutations. This approach has been used successfully in the clinic, with impressive responses being observed when BRAF-mutant melanomas are treated with BRAF inhibitors and the BRAF/MEK inhibitor combination [1] . Despite this, no good targeted therapy strategies exist as yet for the 15-20% of all cutaneous melanomas that are driven by activating mutations in the small GTPase NRAS. Melanomas with NRAS mutations show different biological behavior to their BRAF-mutant counterparts and signal through CRAF, rather than BRAF [2, 3] . In addition, they show constitutive signaling through the PI3K/AKT and Ral-GDS pathways and typically lack inactivation/mutation in the tumor suppressor PTEN [4, 5] . The only strategy with proven efficacy in this melanoma subgroup has been small molecule inhibitors of MEK. In a phase II clinical trial, the MEK inhibitor MEK-162 was associated with response rates of 20%, and a progression-free survival of 3.6 months [6] . Although MEK inhibitor monotherapy is being investigated in a phase III clinical trial, experience with BRAF inhibitors suggests that combination strategies may yield more durable responses.
Melanoma cell lines and tumor specimens express a large number of cell surface receptor tyrosine kinases (RTKs), all with the potential to drive cell growth and survival [7, 8] . There is some preclinical evidence that multitargeted kinase inhibitors, such as RAF-265, may have in-vivo activity against patient-derived BRAF wild-type melanoma xenografts, including those with NRAS Q61R mutations [9] . Here, we present the first preclinical data showing the potential efficacy of the RTK inhibitor amuvatinib (MP470) against NRAS-mutant melanoma.
Materials and methods

Cell culture and reagents
The 1205Lu, WM9, WM793, WM164, WM983A, and WM35 BRAF-mutant as well as the WM1346, WM1366, WM1361A, and Sbcl-2, WM852 NRAS-mutant melanoma cell lines were a generous gift from Dr Meenhard Herlyn (The Wistar Institute, Philadelphia, Pennsylvania, USA). The identities of all cell lines were confirmed by Biosynthesis Inc. (Lewisville, Texas, USA) through STR validation analysis. All cell lines were grown in 5% FBS/RPMI-1640. Amuvatinib was obtained from Selleck Chemicals (Houston, Texas, USA). 
Western blot
Proteins were extracted using RIPA lysis buffer (0.5 mol/l Tris, Triton X-100, Na-deoxycholate, 10% SDS, NaCl, 0.5 mol/l EDTA) containing a Complete Mini Protease Inhibitor Cocktail tablet (Roche, Indianapolis, Indiana, USA). Protein extracts were resolved on Novex 8-16% Tris-glycine gels (Life Technologies, Carlsbad, California, USA) and immunoblotted using antibodies to pAKT, AKT, pERK, ERK, pAxl, Axl, MET, c-KIT, Rad51, and GSK3β from Cell Signaling Technology. Uniform protein loading was confirmed by blotting for GAPDH.
Growth inhibition assay
Cells were plated in a 96-well plate (2.5 × 10 3 per well) and left to attach overnight before being treated with vehicle or increasing doses of amuvatinib for 72 h. Cells were then incubated with MTT reagent (Sigma Aldrich, St. Louis, Missouri, USA) for 3 h and the crystals were solubilized in DMSO, followed by a measurement of absorbance at 570 nm.
Cell cycle analysis
Cells were plated at 60% confluency and allowed to attach overnight in 10 cm plates. They were then treated with vehicle or amuvatinib for 72 h, stained with propidium iodide (Sigma Aldrich), and analyzed by flow cytometry. ModFit Software (Verity Software House, Topsham, Maine, USA) was used for DNA analysis and modeling.
Apoptosis analysis
Cells were allowed to attach in six-well plates overnight, and then treated with vehicle or increasing doses of amuvatinib for 72 h. Cells were then stained with APCconjugated Annexin V (R&D Systems, Minneapolis, Minnesota, USA) and 25 nmol/l tetramethylrhodamine, methyl ester, and perchlorate (TMRM; Molecular Probes, Eugene, Oregon, USA). Staining of cells was then analyzed using flow cytometry. Gates were delineated on the basis of regions of distinct populations.
Three-dimensional spheroid culture
Melanoma spheroid cultures were established using the method described previously [10] . Spheroids were treated with vehicle or increasing doses of amuvatinib for 7 days, and then stained with Calcein-AM (Life Technologies) and propidium iodide.
Colony formation assay
Cells were incubated in six-well plates (1 × 10 4 per well) overnight, before being treated with vehicle or increasing doses of amuvatinib. Cells were left to grow for 2 weeks, with a new drug added twice per week. Wells were stained with a crystal violet solution (50% methanol + 50% H 2 O + 0.5% crystal violet).
Immunofluorescent staining
Cells were plated on glass coverslips in six-well plates and incubated overnight. Cells were then fixed using a 4% paraformaldehyde solution (Electron Microscopy Sciences, Hatfield, Pennsylvania, USA) and permeabilized with 0.2% Triton X-100 before blocking in 1% BSA/PBS. Coverslips were incubated with AlexaFluor 555-conjugated phospho-H2AX antibody (Life Technologies) overnight at 4°C. Coverslips were washed and mounted with ProLong Gold antifade reagent with DAPI (Life Technologies).
Microarray
Microarray data were obtained and their analysis was carried out as outlined previously [11] .
Statistical analysis and IC 50 calculations
Results are reported as mean values; error bars indicating SEM were calculated using GraphPad Prism 6 Software. GraphPad Prism (GraphPad Software, Inc., La Jolla, California, USA) was also used to calculate the IC 50 values for the growth inhibition assay.
Results and discussion
Baseline RTK signaling was investigated in a panel of BRAF-mutant and NRAS-mutant melanoma cell lines using a comprehensive phosphoproteomic approach in which tyrosine-phosphorylated peptides were immunoprecipitated, followed by tandem mass spectrometry (work flow shown in Supplemental Fig. 1A) . It was noted that NRAS-mutant melanoma cell lines had constitutive phosphorylation of Axl, ERBB2, c-MET, EGFR, and ephrins (Fig. 1a) . In all cases, patterns of RTK signaling were heterogeneous and cell line specific. Melanoma cell lines with BRAF V600E mutations showed relatively little basal RTK signaling, with the exceptions of ephrin A4 and one cell line (WM9) with EGFR/ERBB2/ERBB3 activity (Fig. 1a) . The analysis detailed here differs significantly from previous studies of RTK activity in melanoma cell lines in utilizing mass spectrometry to yield precise, quantitative readouts on specific phosphorylation sites (Fig. 1a) [7, 8] . In agreement with previously published studies, we noted basal tyrosine phosphorylation of Axl at Y702 in all of the NRAS-mutant melanoma cell lines that was lacking in those that were BRAF-mutant [12] . A number of studies have implicated TAM family RTKs in melanoma, with work showing that Axl is activated through an autocrine Axl/Gas6 signaling loop to enhance levels of cell invasion [12] .
Amuvatinib is an orally available tyrosine kinase inhibitor with activity against mutant Kit, c-MET, PDGFRα, and Rad51 [13, 14] . Western blot and microarray analysis showed NRAS-mutant melanoma cell lines to express multiple amuvatinib targets including Axl, c-MET, and c-KIT that were generally lacking in BRAF-mutant melanoma cell lines ( Fig. 1b and Supplemental Fig. 1B ).
The expression of other amuvatinib targets such as Rad51 and GSK3β was uniform across both BRAF-mutant and NRAS-mutant melanoma cell lines (Fig. 1b) . In agreement with NRAS-mutant melanoma cell lines expressing multiple amuvatinib targets, the drug was noted to have significant antiproliferative activity in NRAS-mutant, but not BRAF-mutant melanoma cell lines (Fig. 1c) . From a mechanistic standpoint, amuvatinib inhibited the phosphorylation of Axl and AKT in the WM1366 and WM1364 NRAS-mutant melanoma cell lines (Fig. 1d) . In the WM1346 cell line, amuvatinib also inhibited ERK phosphorylation (Fig. 1d ). These observations are in agreement with other studies showing the dual targeting of MEK and PI3K/AKT to have good efficacy in NRAS-mutant melanoma [15] . Although only modest reductions were observed in Rad51 expression in both WM1366 and WM1346 cells, there was evidence of a DNA damage response being induced, as shown by increased γ-H2AX staining (Supplemental Fig. 2) . Previous work has shown amuvatinib to reduce Rad51-mediated homologous DNA repair, leading to enhanced radiation sensitivity [16] .
Analysis of cell cycle distributions showed amuvatinib to have little effect on the accumulation of cells in G1, with increases in the percentage of cells in S and G2/M (Fig. 2a) . As amuvatinib had relatively minor effects on the cell cycle, we next determined the role of apoptosis induction in the observed cytotoxic effects of the drug. It was noted that amuvatinib treatment was associated with a concentration-dependent induction of apoptosis, as shown by rounding up and detachment of cells from the culture vessel, increased Annexin V binding, and loss of mitochondrial membrane potential ( Fig. 2b and Supplemental Fig. 3A) . Under three-dimensional cell culture conditions, amuvatinib showed significant cytotoxic activity on both WM1346 and WM1366 melanoma cell lines as indicated by the loss of cell viability (reduced calcein-AM staining) and increased cell death (increased propidium iodide staining) (Fig. 2c) . The growth inhibition observed with amuvatinib was prolonged, with a long-term suppression of growth observed in 14-day colony formation assays of NRAS-mutant, but not BRAF-mutant melanoma cells ( Fig. 2d and Supplemental  Fig. 3B ). The effects observed were more pronounced and durable than those observed with MEK inhibitors, such as selumetinib and trametinib, where regrowth of colonies was always observed (Rebecca et al., unpublished data).
The ability of oncogenic Ras to activate multiple signaling pathways including MAPK, PI3K/AKT, Ral-GDS, and other small G-proteins has made the development of targeted therapies a challenge [2] . Although attempts are ongoing to develop rational combinations such as PI3K/MEK and MEK/CDK4 inhibitors, these are often associated with toxicity and may not show efficacy in every patient [15, 17] . Kinase inhibitors that target multiple-RTKs may be effective in NRAS-mutant melanoma. It is likely that RTK inhibitors are less effective in BRAF-mutant melanomas because of high levels of feedback inhibition in the MAPK pathway that limits signals through Ras [18] . There is already evidence that RAF-265 has good antitumor activity in a subset of BRAF wild-type melanoma patient-derived xenografts [9] . NRAS-mutant melanoma patients also showed better clinical responses to the combination of sorafenib with carboplatin + paclitaxel than their BRAF-mutant counterparts [19] . Our data add to this and suggest that amuvatinib may be of utility in some NRAS-mutant melanomas, particularly those which are dependent on the targets of this drug. The emerging evidence suggests that NRAS-mutant melanomas are more diverse than BRAF-mutant melanoma, potentially requiring the development of highly personalized therapeutic strategies on a patient-by-patient basis [20] . Enhanced genetic profiling integrated with quantitative proteomic profiling is likely to play a key role in future therapy selection that allows durable responses to be achieved.
